TTIPF (Thiogenesis Therapeutics) Tariff Resilience Score: 5/10 (As of Jun. 24, 2026)


TTIPF Thiogenesis Therapeutics Corp TTIPF
12 GF Score
Price $0.42
! 1 Warning Sign
View Full Analysis

What is Thiogenesis Therapeutics Tariff Resilience Score?

Thiogenesis Therapeutics TTIPF -6.67% 12 Tariff Resilience Score is 5 as of Jun. 24, 2026. GuruFocus rates TTIPF with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,379 Biotechnology companies, Thiogenesis Therapeutics ranks better than 62.22% on this metric.

Thiogenesis Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Thiogenesis Therapeutics has Biotech firm with potential exposure to tariffs on raw materials. Limited historical data on tariff impact. Mitigation through alternative suppliers is feasible, but industry-specific exemptions are limited.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Thiogenesis Therapeutics might have Average Resilient.

Thiogenesis Therapeutics  (OTCPK:TTIPF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Thiogenesis Therapeutics Tariff Resilience Score Related Terms

TTIPF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Thiogenesis Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thiogenesis Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Thiogenesis Therapeutics's Tariff Resilience Score falls into.


TTIPF
12GF Score
Thiogenesis Therapeutics Corp TTIPF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Thiogenesis Therapeutics (TTIPF) has a Tariff Resilience Score of 5 as of Jun. 24, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Thiogenesis Therapeutics ranks #521 out of 1379 companies in the Biotechnology industry, placing it in the top 37.8%.
Is Thiogenesis Therapeutics' Tariff Resilience Score too high?
Thiogenesis Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Thiogenesis Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, Thiogenesis Therapeutics ranks #521 out of 1379 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Thiogenesis Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Thiogenesis Therapeutics' Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thiogenesis Therapeutics ranks #521 out of 1379 companies for Tariff Resilience Score. This puts Thiogenesis Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Thiogenesis Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thiogenesis Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thiogenesis Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thiogenesis Therapeutics stock overvalued right now?
Thiogenesis Therapeutics (TTIPF) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Thiogenesis Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Thiogenesis Therapeutics (TTIPF), the current Tariff Resilience Score is 5 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thiogenesis Therapeutics Business Description

Other Exchanges Q8M:GermanyTTI:Canada
Address 4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also conducting research and clinical development activities for primary mitochondrial diseases, including Leigh syndrome spectrum disorders.
12GF Score

Get the complete analysis for TTIPF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price